Clinical Trial

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

Study acronym: CBD
Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild to moderate Alzheimer's Disease (AD).
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2019-08-29; most recent amendment 2026-03-24.
Status change: Recruiting → Active, Not Recruiting 2026-03-24
Status change: Not Yet Recruiting → Recruiting 2020-02-19
Trial Details
NCT Number NCT04075435
Lead Sponsor Mclean Hospital
Collaborators: Spier Family Foundation
Conditions Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Enrollment 12 participants
Start Date 2021-01-11
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-30